Baxter’s shares traded hands slightly $0.24 higher, hitting $76.58, or 0.31 percent after the company strike a deal to sell its two commercially marketed vaccines and related production facilities to Pfizer Inc. (NYSE:PFE) for a total cash amount of $635 million.

The transaction includes the company’s commercial vaccines business – NeisVAc-C and FSME-IMMUN for the treatment of meningitis and tick-borne encephalitis, respectively. Both products are currently available in several European markets.  Baxter is expected to close the transaction by the end of 2014.

 Baxter International Inc. (NYSE:BAX), a biopharmaceutical company, engages in the development, manufacture and commercialization of products for the treatment of hemophilia, immune disorders, cancer, infectious diseases, kidney disease, trauma and other chronic and acute medical conditions.

Shares of Baxter are currently trading in a range of $76.42 to $77.20. The 52-week range of the stock is $62.80 to $77.31 PS. The company has a market cap of $41.54 billion with a P/E ratio of 21.56.

Source: FINVIZ.com

Read More at: Retail Investor 360